{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:59:47Z","timestamp":1790225987355,"version":"4.1.0"},"reference-count":60,"publisher":"Termedia Sp. z.o.o.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reumatologia"],"published-print":{"date-parts":[[2018,4,30]]},"abstract":"<jats:p>Primary Sj\u00f6gren\u2019s syndrome (pSS) is an autoimmune connective tissue disease affecting the exocrine glands, leading to damage of their structure and impairment of their function. In the course of pSS the internal organs may be involved and the symptoms may concern any system. Neurological disorders are one of the most common extraglandular manifestations of pSS. Available literature data estimate the prevalence of neurological symptoms as about 8.5\u201370% of patients diagnosed with pSS. The most common neurological complication of pSS is peripheral neuropathy, and in particular sensory polyneuropathy. Central nervous system involvement is much less common. There are also reports of various symptoms connected with damage to cranial nerves and the autonomic nervous system. A careful neurological evaluation, combined with neurophysiological tests, is recommended in patients with pSS. This review summarizes the neurological manifestations of pSS, their possible pathogenic mechanisms, diagnostic evaluation and potential treatment.<\/jats:p>","DOI":"10.5114\/reum.2018.75521","type":"journal-article","created":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T12:58:20Z","timestamp":1527598700000},"page":"99-105","source":"Crossref","is-referenced-by-count":125,"title":["Neurological manifestations of primary Sj\u00f6gren\u2019s syndrome"],"prefix":"10.5114","volume":"56","author":[{"given":"Joanna","family":"Perzy\u0144ska-Mazan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Ma\u015bli\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Gasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3061","published-online":{"date-parts":[[2018,5,9]]},"reference":[{"key":"ref-773482","doi-asserted-by":"crossref","unstructured":"Alexander E, Provost T, Stevens M, et al. Neurologic complications of primary Sj\u00f6gren\u2019s syndrome. Medicine (Baltimore) 1982; 61: 247-257.","DOI":"10.1097\/00005792-198207000-00004"},{"key":"ref-773483","doi-asserted-by":"crossref","unstructured":"Fauchais AL, Magy L, Vidal E. Central and peripheral neurological complications of primary Sj\u00f6gren\u2019s syndrome. Presse Med 2012; 41: 485-493.","DOI":"10.1016\/j.lpm.2012.06.002"},{"key":"ref-773484","doi-asserted-by":"crossref","unstructured":"Griffin JW, Cornblath DR, Alexander E, et al. Ataxic sensory neuropathy and dorsal root ganglionitis associated with Sj\u00f6gren\u2019s syndrome. Ann Neurol 1990; 27: 304-315.","DOI":"10.1002\/ana.410270313"},{"key":"ref-773485","doi-asserted-by":"crossref","unstructured":"Chai J, Logigian EL. Neurological manifestations of primary Sj\u00f6gren syndrome. Curr Opin Neurol 2010; 23: 509-513.","DOI":"10.1097\/WCO.0b013e32833de6ab"},{"key":"ref-773486","doi-asserted-by":"crossref","unstructured":"Moutsopoulos HN, Sarmas JH, Talal N. Is central nervous system involvement a systemic manifestation of primary Sj\u00f6gren syndrome? Rheum Dis Clin North Am 1993; 19: 909-912.","DOI":"10.1016\/S0889-857X(21)00212-X"},{"key":"ref-773487","doi-asserted-by":"crossref","unstructured":"Andonopoulos AP, Lagos G, Drosos AA, et al. The spectrum of neurological involvement in Sj\u00f6gren syndrome. Br J Rheumatol 1990; 29: 21-23.","DOI":"10.1093\/rheumatology\/29.1.21"},{"key":"ref-773488","doi-asserted-by":"crossref","unstructured":"Delalande S, de Seze J, Fauchais AL, et al. Neurologic manifestations in primary Sj\u00f6gren syndrome: a study of 82 patients. Medicine (Baltimore) 2004; 83: 280e91.","DOI":"10.1097\/01.md.0000141099.53742.16"},{"key":"ref-773489","doi-asserted-by":"crossref","unstructured":"Mori K, Iijima M, Koike H, et al. The wide spectrum of clinical manifestations in Sj\u00f6gren\u2019s syndrome-associated neuropathy. Brain 2005; 128: 2518-2534.","DOI":"10.1093\/brain\/awh605"},{"key":"ref-773490","doi-asserted-by":"crossref","unstructured":"Le Guern V, Belin C, Henegar C, et al. Cognitive function and 99mTc-ECD brain SPECT are significantly correlated in patients with primary Sj\u00f6gren syndrome: a case-control study. Ann Rheum Dis 2010; 69: 132-137.","DOI":"10.1136\/ard.2008.090811"},{"key":"ref-773491","doi-asserted-by":"crossref","unstructured":"Matar\u00f3 M, Escudero D, Ariza M, et al. Magnetic resonance abnormalities associated with cognitive dysfunction in primary Sj\u00f6gren syndrome. J Neurol 2003; 250: 1070-1076.","DOI":"10.1007\/s00415-003-0153-x"},{"key":"ref-773492","doi-asserted-by":"crossref","unstructured":"Alexander EL, Malinow K, Lejewski JE, et al. Primary Sj\u00f6gren\u2019s syndrome with central nervous system disease mimicking multiple sclerosis. Ann Intern Med 1986; 104: 323-330.","DOI":"10.7326\/0003-4819-104-3-323"},{"key":"ref-773493","doi-asserted-by":"crossref","unstructured":"Thong BY, Venketasubramanian N. A case of Sj\u00f6gren\u2019s syndrome or multiple sclerosis? A diagnostic and therapeutic dilemma. Rheumatol Int 2002; 22: 256-258.","DOI":"10.1007\/s00296-002-0240-9"},{"key":"ref-773494","doi-asserted-by":"crossref","unstructured":"Pillemer SR, Mendelsohn AB, Morgen KE. Central Nervous System involvement. In: Sj\u00f6gren\u2019s Syndrome. Ramos-Casals M (ed.). Springer-Verlag London Ltd, London 2012: 281-291.","DOI":"10.1007\/978-0-85729-947-5_20"},{"key":"ref-773495","doi-asserted-by":"crossref","unstructured":"de Seze J, Devos D, Castelnovo G, et al. The prevalence of Sj\u00f6gren syndrome in patients with primary progressive multiple sclerosis. Neurology 2001; 57: 1359-1363.","DOI":"10.1212\/WNL.57.8.1359"},{"key":"ref-773496","unstructured":"de Seze J, Delalande S, Fauchais AL, et al. Myelopathies secondary to Sj\u00f6gren\u2019s syndrome: treatment with monthly intravenous cyclophosphamide associated with corticosteroids. J Rheumatol 2006; 33: 709-711."},{"key":"ref-773497","doi-asserted-by":"crossref","unstructured":"Zahlane S, Louhab N, El Mellakh M, et al. Anterior horn syndrome: A rare manifestation of primary Sj\u00f6gren\u2019s syndrome. Joint Bone Spine 2016; 83: 448-450.","DOI":"10.1016\/j.jbspin.2016.02.018"},{"key":"ref-773498","doi-asserted-by":"crossref","unstructured":"Hagiwara K, Murai H, Ochi H, et al. Upper motor neuron syndrome associated with subclinical Sj\u00f6gren\u2019s syndrome. Intern Med 2008; 47: 1047-1051.","DOI":"10.2169\/internalmedicine.47.0846"},{"key":"ref-773499","doi-asserted-by":"crossref","unstructured":"G\u00f8ransson LG, Herigstad A, Tjensvoll AB, et al. Peripheral neuropathy in primary Sj\u00f6gren syndrome: a population-based study. Arch Neurol 2006; 63: 1612-1615.","DOI":"10.1001\/archneur.63.11.1612"},{"key":"ref-773500","doi-asserted-by":"crossref","unstructured":"Vrethem M, Lindvall B, Holmgren H, et al. Neuropathy and myopathy in primary Sj\u00f6gren\u2019s syndrome: neurophysiological, immunological and muscle biopsy results. Acta Neurol Scand 1990; 82: 126-131.","DOI":"10.1111\/j.1600-0404.1990.tb01601.x"},{"key":"ref-773501","doi-asserted-by":"crossref","unstructured":"Gemignani F, Marbini A, Pavesi G, et al. Peripheral neuropathy associated with primary Sj\u00f6gren\u2019s syndrome. J Neurol Neurosurg Psychiatry 1994; 57: 983-986.","DOI":"10.1136\/jnnp.57.8.983"},{"key":"ref-773502","doi-asserted-by":"crossref","unstructured":"Barendregt PJ, van den Bent MJ, van Raaij-van den Aarssen VJ, et al. Involvement of the peripheral nervous system in primary Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis 2001; 60: 876-881.","DOI":"10.1016\/S0003-4967(24)43388-8"},{"key":"ref-773503","doi-asserted-by":"crossref","unstructured":"Lopate G, Pestronk A, Al-Lozi M, et al. Peripheral neuropathy in an outpatient cohort of patients with Sj\u00f6gren\u2019s syndrome. Muscle Nerve 2006; 33: 672-676.","DOI":"10.1002\/mus.20514"},{"key":"ref-773504","doi-asserted-by":"crossref","unstructured":"Skopouli FN, Dafni U, Ioannidis JP, et al. Clinical evolution, and morbidity and mortality of primary Sj\u00f6gren\u2019s syndrome. Semin Arthritis Rheum 2000; 29: 296-304.","DOI":"10.1016\/S0049-0172(00)80016-5"},{"key":"ref-773505","doi-asserted-by":"crossref","unstructured":"Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sj\u00f6gren\u2019s syndrome. Arthritis Rheum 2002; 46: 741-747.","DOI":"10.1002\/art.10221"},{"key":"ref-773506","doi-asserted-by":"crossref","unstructured":"Liao CY, Wang CC, Chen IH, et al. Hypokalemic paralysis as a presenting manifestation of primary Sj\u00f6gren\u2019s syndrome accompanied by vitamin D deficiency. Intern Med 2013; 52: 2351-2353.","DOI":"10.2169\/internalmedicine.52.0899"},{"key":"ref-773507","doi-asserted-by":"crossref","unstructured":"Garcia-Carrasco M, Ramos-Casals M, Rosas J. Primary Sj\u00f6gren syndrome: Clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore) 2002; 81: 270-280.","DOI":"10.1097\/00005792-200207000-00003"},{"key":"ref-773508","doi-asserted-by":"crossref","unstructured":"Lafitte C, Amoura Z, Cacoub P, et al. Neurological complications of primary Sj\u00f6gren\u2019s syndrome. J Neurol 2001; 248: 577-584.","DOI":"10.1007\/s004150170135"},{"key":"ref-773509","doi-asserted-by":"crossref","unstructured":"S\u00e8ne D, Jallouli M, Lefaucheur J-P, et al. Peripheral neuropathies associated with primary Sj\u00f6gren syndrome: immunologic profiles of nonataxic sensory neuropathy and sensorimotor neuropathy. Medicine (Baltimore) 2011; 90: 133-138.","DOI":"10.1097\/MD.0b013e31820fd2d1"},{"key":"ref-773510","doi-asserted-by":"crossref","unstructured":"Tanaka K, Nakayasu H, Suto Y, et al. Acute Motor-dominant Polyneuropathy as Guillain-Barr\u00e9 Syndrome and Multiple Mononeuropathies in a Patient with Sj\u00f6gren\u2019s Syndrome. Intern Med 2016; 55: 2717-2722.","DOI":"10.2169\/internalmedicine.55.6881"},{"key":"ref-773511","doi-asserted-by":"crossref","unstructured":"Tob\u00f3n GJ, Pers JO, Devauchelle-Pensec V, et al. Neurological Disorders in Primary Sj\u00f6gren\u2019s Syndrome. Autoimmune Dis 2012; 2012: 645967.","DOI":"10.1155\/2012\/645967"},{"key":"ref-773512","doi-asserted-by":"crossref","unstructured":"Camdessanch\u00e9 JP, Jousserand G, Ferraud K, et al. The pattern and diagnostic criteria of sensory neuronopathy: a case-control study. Brain 2009; 132: 1723-1733.","DOI":"10.1093\/brain\/awp136"},{"key":"ref-773513","doi-asserted-by":"crossref","unstructured":"Jamilloux Y, Magy L, Hurtevent JF, et al. Immunological profiles determine neurological involvement in Sj\u00f6gren\u2019s syndrome. Eur J Intern Med 2014; 25: 177-181.","DOI":"10.1016\/j.ejim.2013.10.005"},{"key":"ref-773514","doi-asserted-by":"crossref","unstructured":"Mochizuki H, Kamakura K, Masaki T, et al. Motor dominant neuropathy in Sj\u00f6gren\u2019s syndrome: report of two cases. Intern Med 2002; 41: 142-146.","DOI":"10.2169\/internalmedicine.41.142"},{"key":"ref-773515","doi-asserted-by":"crossref","unstructured":"Dworkin RH, O\u2019Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007; 132: 237-251.","DOI":"10.1016\/j.pain.2007.08.033"},{"key":"ref-773516","doi-asserted-by":"crossref","unstructured":"Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised <i>placebo<\/i>-controlled trial. Lancet Neurol 2008; 7: 136-144.","DOI":"10.1016\/S1474-4422(07)70329-0"},{"key":"ref-773517","doi-asserted-by":"crossref","unstructured":"Terrier B, Lacroix C, Guillevin L, et al. Diagnostic and prognostic relevance of neuromuscular biopsy in primary Sj\u00f6gren\u2019s syndrome-related neuropathy. Arthritis Rheum 2007; 57: 1520-1529.","DOI":"10.1002\/art.23102"},{"key":"ref-773518","doi-asserted-by":"crossref","unstructured":"Ramos-Casals M, Solans R, Rosas J, et al. Primary Sj\u00f6gren\u2019s syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore) 2008; 87: 210-219.","DOI":"10.1097\/MD.0b013e318181e6af"},{"key":"ref-773519","doi-asserted-by":"crossref","unstructured":"Grant IA, Hunder GG, Homburger HA, et al. Peripheral neuro\u00adpathy associated with sicca complex. Neurology 1997; 48: 855-862.","DOI":"10.1212\/WNL.48.4.855"},{"key":"ref-773520","doi-asserted-by":"crossref","unstructured":"England JD, Gronseth GS, Franklin G, et al. Evaluation of distal symmetric polyneuropathy: the role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Muscle Nerve 2009; 39: 106-115.","DOI":"10.1002\/mus.21227"},{"key":"ref-773521","doi-asserted-by":"crossref","unstructured":"Dalakas MC. Chronic idiopathic ataxic neuropathy. Ann Neurol 1986; 19: 545-554.","DOI":"10.1002\/ana.410190605"},{"key":"ref-773522","doi-asserted-by":"crossref","unstructured":"Pereira PR, Viala K, Maisonobe T, et al. Sj\u00f6gren Sensory Neuro\u00adnopathy (Sj\u00f6gren Ganglionopathy): Long-Term Outcome and Treatment Response in a Series of 13 Cases. Medicine (Baltimore) 2016; 95: e3632.","DOI":"10.1097\/MD.0000000000003632"},{"key":"ref-773523","doi-asserted-by":"crossref","unstructured":"Souayah N, Chong PS, Cros D. Acute sensory neuronopathy as the presenting symptom of Sj\u00f6gren\u2019s syndrome. J Clin Neurosci 2006; 13: 862-865.","DOI":"10.1016\/j.jocn.2005.12.029"},{"key":"ref-773524","doi-asserted-by":"crossref","unstructured":"Takahashi Y, Takata T, Hoshino M, et al. Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sj\u00f6gren\u2019s syndrome. IV immunoglobulin. Neurology 2003; 60: 503-505.","DOI":"10.1212\/01.WNL.0000046680.47883.7D"},{"key":"ref-773525","doi-asserted-by":"crossref","unstructured":"Chen WH, Yeh JH, Chiu HC. Plasmapheresis in the treatment of ataxic sensory neuropathy associated with Sj\u00f6gren\u2019s syndrome. Eur Neurol 2001; 45: 270-274.","DOI":"10.1159\/000052142"},{"key":"ref-773526","doi-asserted-by":"crossref","unstructured":"Yamada S, Mori K, Matsuo K, et al. Interferon alfa treatment for Sj\u00f6gren\u2019s syndrome associated neuropathy. J Neurol Neuro\u00adsurg Psychiatry 2005; 76: 576-578.","DOI":"10.1136\/jnnp.2004.049502"},{"key":"ref-773527","doi-asserted-by":"crossref","unstructured":"Lacomis D. Small-fiber neuropathy. Muscle Nerve 2002; 26: 173-188.","DOI":"10.1002\/mus.10181"},{"key":"ref-773528","doi-asserted-by":"crossref","unstructured":"Mori K, Iijima M, Sugiura M, et al. Sj\u00f6gren\u2019s syndrome associated painful sensory neuropathy without sensory ataxia. J Neurol Neurosurg Psychiatry 2003; 74: 1320-1322.","DOI":"10.1136\/jnnp.74.9.1320"},{"key":"ref-773529","doi-asserted-by":"crossref","unstructured":"Amoura Z, Salachas F, Cacoub B, et al. Pseudosclerose laterale amyotrophiqueau tours du syndrome de Gougerot-Sj\u00f6gren primitif. Rev Med Interne 1999; 20: 83s.","DOI":"10.1016\/S0248-8663(99)80232-X"},{"key":"ref-773530","doi-asserted-by":"crossref","unstructured":"Attout L, Rahmeh F, Ziegler L. Syndrome de Gougerot-Sj\u00f6gren simulant unesclerose laterale amyotrophique. Rev Med Interne 2000; 21: 708-710.","DOI":"10.1016\/S0248-8663(00)80030-2"},{"key":"ref-773531","doi-asserted-by":"crossref","unstructured":"Katz JS, Houroupian D, Ross MA. Multisystem neuronal involvement and sicca complex: broadening the spectrum of complications. Muscle Nerve 1999; 22: 404-407.","DOI":"10.1002\/(SICI)1097-4598(199903)22:3<404::AID-MUS15>3.0.CO;2-E"},{"key":"ref-773532","doi-asserted-by":"crossref","unstructured":"Rafai MA, Boulaajaj FZ, Moutawakil F, et al. Neurological manifestations revealing primitive Gougerot-Sj\u00f6gren syndrome: 9 cases. Joint Bone Spine 2009; 76: 139-145.","DOI":"10.1016\/j.jbspin.2008.03.010"},{"key":"ref-773533","unstructured":"Lindvall B, Bengtsson A, Ernerudh J, et al. Subclinical myositis is common in primary Sj\u00f6gren\u2019s syndrome and is not related to muscle pain. J Rheumatol 2002; 29: 717-725."},{"key":"ref-773534","doi-asserted-by":"crossref","unstructured":"Kanellopoulos P, Baltoyiannis C, Tzioufas AG. Primary Sj\u00f6gren\u2019s syndrome associated with inclusion body myositis. Rheumatology (Oxford) 2002; 41: 440-444.","DOI":"10.1093\/rheumatology\/41.4.440"},{"key":"ref-773535","doi-asserted-by":"crossref","unstructured":"Misterska-Sk\u00f3ra M, Sebastian A, Dzi\u0119giel P, et al. Inclusion body myositis associated with Sj\u00f6gren\u2019s syndrome. Rheumatol Int 2013; 33: 3083-3086.","DOI":"10.1007\/s00296-012-2556-4"},{"key":"ref-773536","unstructured":"Hung YM, Huang NC, Wann SR, et al. Recurrent Hypokalemic Periodic Paralysis UnmasksSj\u00f6gren Syndrome without Sicca Symptoms. J Coll Physicians Surg Pak 2015; 25 Suppl 1: S36-S38."},{"key":"ref-773537","unstructured":"Andonopoulos AP, Christodoulou J, Ballas C, et al. Autonomic cardiovascular neuropathy in Sj\u00f6gren\u2019s syndrome. A controlled study. J Rheumatol 1998; 25: 2385-2388."},{"key":"ref-773538","doi-asserted-by":"crossref","unstructured":"Waterman SA, Gordon TP, Rischmueller M. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sj\u00f6gren\u2019s syndrome. Arthritis Rheum 2000; 43: 1647-1654.","DOI":"10.1002\/1529-0131(200007)43:7<1647::AID-ANR31>3.0.CO;2-P"},{"key":"ref-773539","doi-asserted-by":"crossref","unstructured":"Dawson L, Tobin A, Smith P, et al. Antimuscarinic antibodies in Sj\u00f6gren\u2019s syndrome: where are we, and where are we going? Arthritis Rheum 2005; 52: 2984-2995.","DOI":"10.1002\/art.21347"},{"key":"ref-773540","doi-asserted-by":"crossref","unstructured":"Fox RI, Stern M. Sj\u00f6gren\u2019s syndrome: mechanisms of pathogenesis involve interaction of immune and neurosecretory systems. Scand J Rheumatol 2002; 116: 3-13.","DOI":"10.1080\/0300974023208178882"},{"key":"ref-773541","doi-asserted-by":"crossref","unstructured":"Dawson LJ, Caulfield VL, Stanbury JB, et al. Hydroxychloroquine therapy in patients with primary Sj\u00f6gren\u2019s syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. Rheumatology 2005; 44: 449-455.","DOI":"10.1093\/rheumatology\/keh506"}],"container-title":["Rheumatology"],"original-title":[],"link":[{"URL":"https:\/\/reu.termedia.pl\/pdf-89708-85710","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reu.termedia.pl\/pdf-89708-85710","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T20:38:48Z","timestamp":1751661528000},"score":1,"resource":{"primary":{"URL":"https:\/\/reu.termedia.pl\/Neurological-manifestations-of-primary-Sjogren-s-syndrome,89708,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,30]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"alternative-id":["89708"],"URL":"https:\/\/doi.org\/10.5114\/reum.2018.75521","relation":{},"ISSN":["0034-6233","2084-9834"],"issn-type":[{"value":"0034-6233","type":"print"},{"value":"2084-9834","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,30]]}}}